Scribe Therapeutics
About
Platform
Pipeline
Newsroom
Careers
Investor Relations
Contact
LinkedIn
Twitter or X
Menu
Close
Newsroom
Keep up with the latest
Featured
This Scientist Is Building Custom Gene-Editing Tools
This Scientist Is Building Custom Gene-Editing Tools
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Epigenetic editors are a gentler form of gene editing
February 24, 2025
The Economist
Epigenetic editors are a gentler form of gene editing
February 24, 2025
CRISPR 2.0, the Next Generation
June 21, 2024
Aspen Ideas: Health
CRISPR 2.0, the Next Generation
June 21, 2024
The Age of CRISPR: Engineering the Future of Genetic Medicine
February 23, 2024
TEDxBerkeley
The Age of CRISPR: Engineering the Future of Genetic Medicine
February 23, 2024
Media Center
All
Media Highlights
Press Releases
Media
Exciting new CRISPR-CasX variant could be ‘Swiss army knife’ for genetics
February 5, 2019
Silicon Republic
Read Now
Press Release
Exciting new CRISPR-CasX variant could be ‘Swiss army knife’ for genetics
February 5, 2019
Silicon Republic
Read Now
Previous
Media
Scribe’s Genetic Editing Aims to Prevent Heart Attacks
July 27, 2026
Barron's
Read Now
Media
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
July 24, 2026
Fierce Biotech
Read Now
Media
Eli Lilly-Backed Scribe Therapeutics Soars 44% After IPO
July 24, 2026
Bloomberg News
Read Now
Media
Scribe Bets on a New Era of Gene Editing
July 24, 2026
Bloomberg Tech
Read Now
Media
Scribe prices upsized IPO before producing human efficacy data
July 24, 2026
Axios
Read Now
Media
CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO
July 24, 2026
MedCity News
Read Now
Load More
Press release
Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
May 21, 2026
Read Now
Press release
Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing
May 18, 2026
Read Now
Press release
Scribe Therapeutics to Highlight Engineered CRISPR Platform Advances and Lead Cardiometabolic Pipeline at ASGCT and EAS Congress 2026
April 30, 2026
Read Now
Press release
Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company
February 17, 2026
Read Now
Press release
Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction
January 20, 2026
Read Now
Press release
Scribe Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 15, 2025
Read Now
Previous
Load More
Publications
Publication
Sequential Proofreading Enhances Specificity and Potency of CRISPR-CasX-based Epigenetic Repressors
August 31, 2026
bioRxiv
Read Now
Publication
Engineered Allosteric Control Enhances Specificity and Potency of CRISPR-CasX-based Epigenetic Repressors
January 14, 2026
bioRxiv
Read Now
Publication
Single particle charge detection mass spectrometry enables molecular characterization of lipid nanoparticles and mRNA packaging
May 18, 2025
Journal of Controlled Release
Read Now
Publication
CasX enzymes comprise a distinct family of RNA-guided genome editors
February 4, 2019
Nature
Read Now
Publication
Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes
May 1, 2017
Nature Biotechnology
Read Now
Publication
Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery
March 2, 2017
Nucleic Acids Research
Read Now
Publication
Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch
June 1, 2016
Nature Biotechnology
Read Now
Publication
Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing
January 7, 2016
Nature Communications
Read Now
Publication
Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery
December 15, 2014
eLife
Read Now
Publication
Programmable RNA recognition and cleavage by CRISPR/Cas9
December 11, 2014
Nature
Read Now
Publication
MicroRNA-mediated switching of chromatin-remodelling complexes in neural development
July 30, 2009
Nature
Read Now